กำลังโหลด
HKSEHealthcareBiotechnology
ข้อมูลล่าสุด
HK$28.60
+HK$0.44 · +1.56%
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
ข้อมูลล่าสุด
HK$28.60
+HK$0.44 · +1.56%
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
ช่วงราคารายวัน
ปัจจุบัน HK$28.60
ช่วง 52 สัปดาห์
ปัจจุบัน HK$28.60
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
ช่วงราคารายวัน
ปัจจุบัน HK$28.60
ช่วง 52 สัปดาห์
ปัจจุบัน HK$28.60
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
iShares Core MSCI Emerging Markets ETFIEMG3.81M0.00%160.25B USD0.09%US$81.40+1.12%
iShares Genomics Immunology and Healthcare ETFIDNA1.92M0.63%319.88M USD0.47%US$42.17+4.33%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX246.14K0.04%664.9M USD0.65%US$71.64+1.00%
iShares MSCI China Small-Cap ETFECNS161.46K0.26%62.09M USD0.59%US$27.45+1.72%
iShares Core MSCI Total International Stock ETFIXUS84.68K0.00%58.62B USD0.07%US$94.99+0.90%
iShares MSCI Emerging Markets Small-Cap ETFEEMS75.35K0.02%390.02M USD0.72%US$76.085+0.76%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM66.03K0.00%1.8B USD0.09%US$87.44+0.55%
State Street SPDR S&P China ETFGXC34.45K0.01%446.48M USD0.59%US$86.47+1.87%iShares Core MSCI Emerging Markets ETFIEMGiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR S&P Emerging Markets Small Cap ETFEWXiShares MSCI China Small-Cap ETFECNSiShares Core MSCI Total International Stock ETFIXUSiShares MSCI Emerging Markets Small-Cap ETFEEMSState Street SPDR Portfolio MSCI Global Stock Market ETFSPGMState Street SPDR S&P China ETFGXCเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน
